Latest From Valneva SE
Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.
- Synthesis Technologies, Production Processes
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Valneva SE
- Senior Management
Thomas Lingelbach , Pres. & CEO
David Lawrence, CFO
Franck Grimaud, CBO
Wolfgang Bender, MD, PhD, CMO
- Contact Info
Phone: (33) 2 28 07 37 10
Campus Bio-Ouest | 6, Rue Alain Bombard
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.